AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 6 - (NewsRx.com & NewsRx.net) -- Avax Technologies, Inc., (AVXT) announced the submission of investigational new drug applications (IND) for M-Vax and O-Vax, its AC Vaccine technology product candidates for the treatment of melanoma and ovarian cancers, with the U.S. Food and Drug Administration (FDA).
If, after a 30-day review period FDA has no questions, the company will be able to commence its clinical trials.
David L. Tousley, president and chief operating officer of Avax stated, "This is an important milestone in the continuing development of the frozen AC Vaccine technology. Our team has done a great job in completing the necessary product development activities, assay development and facility and quality system modifications leading to the submission of these INDs and ensuring that we are ready to carry out the clinical trials."
The endpoints for these ...